Assuntos
Anticoagulantes/administração & dosagem , Coagulação Sanguínea/efeitos dos fármacos , Tratamento Farmacológico da COVID-19 , Monitoramento de Medicamentos , Enoxaparina/administração & dosagem , Fator Xa/análise , Heparina de Baixo Peso Molecular/administração & dosagem , Trombose/prevenção & controle , Idoso , Idoso de 80 Anos ou mais , Anticoagulantes/efeitos adversos , Biomarcadores/sangue , COVID-19/complicações , COVID-19/diagnóstico , Enoxaparina/efeitos adversos , Feminino , Heparina de Baixo Peso Molecular/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Retrospectivos , Trombose/sangue , Trombose/diagnóstico , Trombose/etiologia , Resultado do TratamentoRESUMO
Procalcitonin is a specific marker of severe bacterial infections with systemic inflammation. Quantitative evaluation of serum procalcitonin was performed in 140 patients with Legionella pneumonia. Positive values (>0.5 ng/mL) were found in 57.1% of the subjects. The positive sample rate was higher in early sera (73.9% in the first week) and decreased progressively. Mean values and the positive sample rate (69.8%) were higher in sera collected in the first 2 weeks of disease. Procalcitonin was positive in 86.7% of legionellosis cases confirmed by culture and mean positive values were significantly higher (P < 0.001) than those of culture-negative subjects. We conclude that procalcitonin can represent a useful prognostic marker for severe suspected Legionella pneumonia in the first 2 weeks of disease.
